No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T13:21:17.716Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T13:21:17.716Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Cingulate Inc. (CING) stock was $4.75 as of Oct 5, 2026, 4:00 PM EDT, down 0.21% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +13.6% · 3-year avg -68.3%/yr
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD).
Biotechnology · Kansas City, KS
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.48
Revenue Est.
$540000.00
Last Quarter Results
EPS
$-0.45
vs Estimate
$-0.56
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CING | $63.98M | $4.75 | -0.21% | +13.57% | N/A | N/A | N/A |
| 2INCR | $64.56M | $5.45 | +0.55% | -32.59% | -30.85% | N/A | vs CING |
| 3GOSS | $65.08M | $10.65 | -0.56% | -94.75% | -59.51% | N/A | vs CING |
| 4KLRS | $61.77M | $2.83 | +4.81% | -57.21% | -81.13% | N/A | vs CING |
| 5ALPS | $66.56M | $0.40 | +1.27% | N/A | N/A | N/A | vs CING |
| 6PDSB | $67.11M | $1.20 | +60.32% | +17.56% | -39.13% | -40.75% | vs CING |
forward FY estimate
N/A
$0.00
vs Estimate
$166667.00
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$4.75
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.50 | $-0.43 | $-0.35 | 3 |
| Quarter ending Dec 2026 | $-0.73 | $-0.43 | $0.07 | 3 |
| Quarter ending Mar 2027 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Quarter ending Jun 2027 | $-0.38 | $-0.38 | $-0.38 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.32 | $-2.13 | $-1.99 | 4 |
| FY 2027 | $-4.58 | $-1.75 | $3.60 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $540000.00 | $540000.00 | $540000.00 | 3 |
| Quarter ending Dec 2026 | $2.36M | $2.36M | $2.36M | 3 |
| Quarter ending Mar 2027 | $4.63M | $4.63M | $4.63M | 1 |
| Quarter ending Jun 2027 | $250000.00 | $250000.00 | $250000.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.04M | $2.90M | $5.61M | 3 |
| FY 2027 | $1.31M | $12.17M | $32.72M | 4 |
